Cantor Fitzgerald Estimates Verona Pharma FY2025 Earnings

Verona Pharma plc (NASDAQ:VRNA - Free Report) - Analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Verona Pharma in a note issued to investors on Wednesday, June 11th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company will post earnings of $0.14 per share for the year, up from their previous estimate of $0.10. Cantor Fitzgerald currently has a "Overweight" rating and a $100.00 price target on the stock. The consensus estimate for Verona Pharma's current full-year earnings is ($1.95) per share. Cantor Fitzgerald also issued estimates for Verona Pharma's FY2026 earnings at $1.31 EPS.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.49. The firm had revenue of $98.65 million for the quarter, compared to analyst estimates of $41.47 million.

Several other equities research analysts also recently commented on the company. HC Wainwright boosted their price objective on Verona Pharma from $85.00 to $90.00 and gave the company a "buy" rating in a report on Monday, June 2nd. Roth Capital set a $83.00 price target on shares of Verona Pharma in a research note on Friday, February 28th. TD Cowen began coverage on shares of Verona Pharma in a research note on Monday, April 28th. They issued a "buy" rating and a $100.00 price objective on the stock. Wells Fargo & Company lifted their price objective on shares of Verona Pharma from $93.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, April 30th. Finally, Jefferies Financial Group upped their target price on shares of Verona Pharma from $95.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $87.44.

Verona Pharma Trading Down 0.3%

Shares of VRNA stock traded down $0.30 during mid-day trading on Friday, hitting $92.20. The company's stock had a trading volume of 754,182 shares, compared to its average volume of 1,323,364. The company has a market cap of $7.48 billion, a PE ratio of -48.02 and a beta of 0.21. The company has a debt-to-equity ratio of 0.93, a quick ratio of 12.88 and a current ratio of 13.03. The company's fifty day simple moving average is $70.32 and its 200-day simple moving average is $59.90. Verona Pharma has a 52 week low of $14.14 and a 52 week high of $94.03.

Insider Activity at Verona Pharma

In other news, CEO David Zaccardelli sold 400,000 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the transaction, the chief executive officer now directly owns 13,190,168 shares of the company's stock, valued at approximately $150,367,915.20. The trade was a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mark W. Hahn sold 204,864 shares of the company's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $9.33, for a total value of $1,911,381.12. Following the sale, the chief financial officer now owns 12,678,992 shares in the company, valued at $118,294,995.36. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,885,800 shares of company stock valued at $19,134,481. 4.80% of the stock is owned by corporate insiders.

Institutional Trading of Verona Pharma

A number of institutional investors have recently bought and sold shares of the company. NBC Securities Inc. bought a new stake in Verona Pharma during the first quarter valued at about $34,000. Geneos Wealth Management Inc. lifted its stake in shares of Verona Pharma by 44.2% during the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after acquiring an additional 193 shares during the period. Vermillion Wealth Management Inc. acquired a new stake in shares of Verona Pharma during the fourth quarter worth $46,000. Acadian Asset Management LLC bought a new stake in shares of Verona Pharma in the 1st quarter valued at $48,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Verona Pharma during the first quarter worth $58,000. Institutional investors and hedge funds own 85.88% of the company's stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.